The year 2017 was selected as the starting point due to a significant surge in studies on diabetic kidney disease and the role of TLR4 in inflammatory pathways, alongside the rapid emergence of research on novel therapeutic strategies, such as TLR inhibitors, marking a pivotal milestone in the field. This evidence concerns the gene TLR4 and diabetic kidney disease.